{"protocolSection":{"identificationModule":{"nctId":"NCT05124353","orgStudyIdInfo":{"id":"Neuroprotective 1/2021"},"organization":{"fullName":"Pomeranian Medical University Szczecin","class":"OTHER"},"briefTitle":"Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT","officialTitle":"Evaluation of the Effect of Early Administration of Neuroprotective Drug (Cerebrolysin) on the Outcome of Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy"},"statusModule":{"statusVerifiedDate":"2021-11","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-04-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-04-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2023-04-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-06-25","studyFirstSubmitQcDate":"2021-11-07","studyFirstPostDateStruct":{"date":"2021-11-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-11-07","lastUpdatePostDateStruct":{"date":"2021-11-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Klaudyna Kojder","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Pomeranian Medical University Szczecin"},"leadSponsor":{"name":"Pomeranian Medical University Szczecin","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"Background:\n\nStroke is the third major cause of death and disability worldwide. It was shown that combining early reperfusion therapy (thrombolysis and/or thrombectomy) with stroke unit care and immediate rehabilitation have beneficial effects on the patient recovery and outcomes. Cerebrolysin that was proven to have s neuroprotective and neurotrophic effects in vitro and in vivo, administered in combination with endovascular therapy (EVT) could have a positive impact on the prognosis and outcome of these patients.\n\nObjectives:\n\nTo evaluate the impact of early administration of neuroprotective drug (Cerebrolysin) in patient undergoing EVT on the outcome of patients diagnosed with acute ischemic stroke.\n\nMethods:\n\n100 patients will be recruited to the proposed study according to the inclusion criteria:\n\nInclusion criteria:\n\nAcute ischemic stroke patients NIHSS\\>8 Qualification for mechanical thrombectomy, without previous thrombolysis. The patients will be randomized into 2 subgroups: G1(standard dose of Cerebrolysin 30ml), - G2 (No Cerebrolysin).\n\nThe patients will be randomized into 2 subgroups: G1(standard dose of Cerebrolysin 30ml), - G2 (No Cerebrolysin). Cerebrolysin will be administered immediately after randomization or at the latest during the EVT procedure and will be continued for 10 days. After the EVT all patients, depending on their clinical condition, will be hospitalized in ICU (intensive care unit) or Neurology Department, where standard treatment and monitoring will be implemented, as well as standard rehabilitation. Outcome assessments will include: the NIH Stroke Scale, modified Rankin Score, pre MRS, IQ code, Geriatric Depression Scales, MoCA. Additionally, the infarct volume of the control CT will be measured. The follow up should be performed on day 7( or discharge), 1 month, 3 months, 6 months. The duration of the study is planned forr: 12 -24 months","detailedDescription":"Introduction:\n\nAcute ischemic stroke is one of the main leading cause of death and disability in the world. In proposed project we evaluate the impact of the combination of early reperfusion therapy (thrombectomy) with early neuroproptective drug administration on treatment results in patients with acute ischemic stroke. Cerebrolysin, which has been shown to have neuroprotective and neurotrophic effects in vitro and in vivo, when administered early in combination with early endovascular therapy may have a positive effect on the prognosis and treatment outcomes of these patients. The proposed study, is approved by the Pomeranian Medical University Bioethics Committee in Szczecin, Poland, will be also part of the international CERECAP project investigating the co-application of neuroprotective and reperfusion therapies (thrombolysis, thrombectomy) in patients with acute ischemic stroke.\n\nPurpose of the project:\n\nexamining the impact of early cerebrolysin supply on the treatment effect in patients with diagnosed acute ischemic stroke, qualified for endovascular treatment in the form of thrombectomy\n\nHypothesis:\n\nCerebrolysin in early (up do 6 h) administration with combination of early (up to 6h) endovascular therapy (thrombectomy) is beneficial for the patients with acute ischemic stroke diagnosis.\n\nMaterial and method 100 patients will be qualified for the proposed project. Study duration: 24 months.\n\nInclusion criteria for the study diagnosis of acute ischemic stroke qualification for endovascular treatment in the form of thrombectomy\n\nCriteria for exclusion from the study:\n\nPatient qualified for thrombolysis Patients under 18 years of age pregnancy Kidney failure Epilepsy History of allergy to cerebrolysin\n\nStudy design:\n\nAfter prior randomization to the group, patients will be divided into group G1 (cerebrolysin supply) and group G2 (standard treatment, without cerebrolysin supply).\n\nIn group G1, cerebrolysin will be administered immediately after qualifying for the study (i.e. up to 6 hours after the onset of symptoms) and continued for the next 10 days at a dose of 30 ml i.v.\n\nPatients from both groups G1 and G2 will undergo thrombectomy treatment, and then, depending on the clinical condition, hospitalized in the Intensive Care Unit or the Department of Neurology with the Stroke Department.\n\nDuring the hospitalization, the standard and typical care for both departments will be continued.\n\nTreatment results will be assessed using:\n\nNIH, Modified Rankin Scale, preMRS, IQ code, Geriatric Depression Scale and MoCA.\n\nRoutine checkups for computed tomography will also undergo analysis for treatment evaluation (e.g. stroke volume). Patients' condition will be assessed after 1, 3 and 6 months.\n\nThe results obtained in this way will be statistically analyzed and presented in the form of articles in medical journals.\n\nExpected benefits:\n\n* examination of the influence of early cerebrolysin supply on the treatment effect in patients undergoing thrombectomy after acute ischemic stroke diagnosis\n* development of the cerebrolysin supply protocol in patients with acute ischemic stroke diagnosis"},"conditionsModule":{"conditions":["Stroke, Acute, Ischemic"],"keywords":["acute.stroke","ischemic stroke","neuroprotection","treatment"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":100,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"G1 : Treatment Group (TG)r","type":"ACTIVE_COMPARATOR","description":"Patients in TG receive neuroprotective drug: standard dose of Cerebrolysin 30ml i.v. in the first 6 hours after first symptoms. After EVT the administration is continued for 10 days.","interventionNames":["Drug: Cerebrolysin"]},{"label":"G2 : Control Group (CG)","type":"NO_INTERVENTION","description":"Patients in CG receive no additional i.v. treatment."}],"interventions":[{"type":"DRUG","name":"Cerebrolysin","description":"Cerebrolysin 30ml i.v., administrated in first 6 hours after stroke onset and fo 10 day afterwards in Neurology Department or ICU conditions.","armGroupLabels":["G1 : Treatment Group (TG)r"],"otherNames":["neuroprotective treatment"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Survival","description":"survival rate within first 6 months","timeFrame":"6 months"},{"measure":"NIHSS","description":"NIH Stroke Scale","timeFrame":"day 1"},{"measure":"NIHSS","description":"NIH Stroke Scale","timeFrame":"month 3"},{"measure":"NIHSS","description":"NIH Stroke Scale","timeFrame":"month 6"},{"measure":"Rankin","description":"modified Rankin Score","timeFrame":"day 1"},{"measure":"Rankin","description":"modified Rankin Score","timeFrame":"month 3"},{"measure":"Rankin","description":"modified Rankin Score","timeFrame":"month 6"},{"measure":"pre MRS","description":"modified pre Rankin Score","timeFrame":"day 1"},{"measure":"pre MRS","description":"modified pre Rankin Score","timeFrame":"month 3"},{"measure":"pre MRS","description":"modified pre Rankin Score","timeFrame":"month 6"},{"measure":"IQ code","description":"IQ code","timeFrame":"month 3"},{"measure":"IQ code","description":"IQ code","timeFrame":"month 6"},{"measure":"Geriatric Depression Scales","description":"Geriatric Depression Scales","timeFrame":"month 3"},{"measure":"Geriatric Depression Scales","description":"Geriatric Depression Scales","timeFrame":"month 6"},{"measure":"IV","description":"infarct volume of the control CT","timeFrame":"10 days"},{"measure":"modified treatment in cerebral infarction (mTICI score)","description":"measure the reperfusion grade post thrombectomy - radiological imaging","timeFrame":"1 month"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* acute ischemic stroke diagnosis,\n* qualification for mechanical thrombectomy, without previous thrombolysis\n* age \\>18\n\nExclusion Criteria:\n\n* age \\<18\n* pregnancy\n* cerebrolysin allergy\n* epilepsy\n* renal failure\n* thrombolysis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Klaudyna Kojder","role":"CONTACT","phone":"+48692581426","phoneExt":"+48","email":"klaudynakojder@gmail.com"}],"overallOfficials":[{"name":"Konrad Jarosz","affiliation":"Pomeranian Medical Univerisity","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Pomeranian Medical University, University Hospital no.1","status":"RECRUITING","city":"Szczecin","country":"Poland","contacts":[{"name":"Klaudyna Kojder","role":"CONTACT","phone":"+48692581426","phoneExt":"+48","email":"klaudynakojder@gmail.com"},{"name":"Klaudyna Kojder","role":"CONTACT","email":"klaudynakojder@gmail.com"},{"name":"Agata Andrzejewska","role":"SUB_INVESTIGATOR"},{"name":"Joanna SoÅ‚ek-Pastuszka","role":"SUB_INVESTIGATOR"},{"name":"Anna Bajer-Czajkowska","role":"SUB_INVESTIGATOR"},{"name":"Marta Masztalewicz","role":"SUB_INVESTIGATOR"},{"name":"Artur Reginia","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":53.42894,"lon":14.55302}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000006952","term":"Cerebrolysin"}],"ancestors":[{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018697","term":"Nootropic Agents"}],"browseLeaves":[{"id":"M351658","name":"Cerebrolysin","asFound":"VII","relevance":"HIGH"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"M20464","name":"Nootropic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"NootAg","name":"Nootropic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}